The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Improving CAR T-cell therapy referral patterns of patients with R/R LBCL in the US
In this video, Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, discusses the challenge of improving CAR T-cell therapy referral patterns of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the United States. Dr Graff emphasizes the importance of better communication and education of community physicians on when to refer patients, as well as a multidisciplinary approach to patient management. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
